Home

UNIHEALTH — Deck

Unihealth Hospitals Ltd · UNIHEALTH · NSE SME

A 120-bed Uganda hospital funding a four-hospital India bet — and reporting profits that don't convert to cash

₹449
CMP
₹705 Cr
Market cap
29.2x
P/E (TTM)
33%
FY25 OPM (48% in H1 FY26)
75% of revenue from one Ugandan hospital, 9% three-year cash conversion, Nashik 200-bed commissioning due Jun 2026
1 · Business

An India-Africa hospital platform that is, today, one 120-bed hospital in Kampala

  • Hospitals (82% of rev). UMC Victoria Kampala — 120 beds, 72% occupancy, ARPOB jumped from ₹24K to ₹40K in H1 FY26 via super-specialty add-ons.
  • Distribution & consultancy (13%). Pharma trade and project consultancy across India-Africa — small, sticky, but not the engine.
  • India build-out. Navi Mumbai 52-bed live (Oct 2025); Nashik 200-bed due Jun 2026; Pune 125-bed in FY27 — asset-light leased model.
No moat in the structural sense — what works in Uganda is low competition + a sovereign anchor payer + a 10-year tax holiday.
2 · Numbers

Record paper profits, negative cash flow — the divergence is the whole story

₹56 Cr
FY25 Revenue (was ₹22 Cr in FY20)
-₹3 Cr
FY25 Op Cash Flow (₹15 Cr net profit)
328
Debtor Days FY25 (was 206 in FY20)
9%
3-yr Cash Conversion (peers: 70-90%)

H1 FY26 inflection is real (₹67 Cr revenue, 48% OPM, ₹29 Cr PAT) but flatters by combining peak Uganda utilization with a 10-year tax holiday and zero India ramp drag.

3 · People

Governance B- — frugal founders, oversized ambitions, undersized board

  • Ownership. Promoters 69.14% (rising), zero pledge, zero selling — Dr. Parmar's family extended ₹4.4 Cr in personal loans to the company.
  • Pay. MD draws ₹60 lakhs (0.39x median employee); co-founder Dr. Shah takes zero. Genuinely lean, not optical.
  • Board. 5 members, 2 independent, no Africa or large-chain expertise; only 21 standalone employees governing 5-country operations.
  • Related parties. Up to ₹80 Cr/yr of RPTs approved (vs ₹58 Cr consol revenue) — flows through Mauritius/Tanzania/Uganda subsidiaries.
4 · Story

From medical-tour startup to Africa hospital operator to India re-entry

Phase 1 (2010-2023): 13 years bootstrapping — Uganda + Nigeria hospitals, Tanzania dialysis, small pharma trade. NSE SME IPO Sep 2023 at ₹135.

Phase 2 (FY24-FY25): Layered expansion pitch — 1,000-bed target, syringe factory, airline med-tourism. Most quietly retired.

Phase 3 (H2 FY25-now): Real India entry. Navi Mumbai live; Nashik commissioning imminent. Genuine inflection, but execution risk multiplied 4x.

Credibility 5/10 — margins beat guidance, but bed-count and diversification targets have repeatedly slipped without acknowledgement.
5 · Web Intel

What the internet knows that the filings don't say

  • Morningstar 127% premium. Quant model flags fair-value gap despite sub-sector P/E — suggests the rerating priced in growth not yet delivered.
  • 85% rally in 7 sessions. SME float (~30% public) makes the price as volatile up as down — momentum, not consensus.
  • Zero institutional coverage. No FII, 0.75% DII, no sell-side analyst — investors are flying blind on consensus estimates.
FY26 audited results are imminent — the trading window already closed Apr 1, 2026. First full read on India ramp drag.
6 · Risks

Four material risks — receivables and execution dominate

  • Sovereign receivables concentration. ₹82 Cr of ₹112 Cr receivables from Uganda Ministry of Defense on a 9-13 month cycle.
  • Execution bandwidth. 21 standalone staff and 5-member board commissioning Navi Mumbai + Nashik + Pune + Mwanza in parallel.
  • Margin compression mechanic. Indian facilities start at 15-18% EBITDA vs. Uganda's 48% — blended OPM falls as Nashik scales.
  • Liquidity / SME listing. ~1,058 shareholders, no analyst coverage, thin float — entry and exit are constrained either way.
7 · What's Next

Two earnings prints and a 200-bed commissioning before October — most open questions resolve

  • Apr 30, 2026. FY2026 audited board meeting — trading window already closed Apr 1; first full-year print since the H1 FY26 inflection.
  • May 15, 2026. FY2026 results call — whether the H1 ₹140 Cr revenue run-rate held into H2 with India ramp drag.
  • Jun 15, 2026. Nashik 200-bed commissioning (delayed from Jan-Feb) — biggest single execution event in company history.
  • Jul 31, 2026. Q1 FY27 update — first standalone Navi Mumbai quarter; tests the ₹27-28K Indian ARPOB target.
  • Sep 30, 2026. Q2 FY27 receivables snapshot — whether Indian cash-and-insurance mix actually pulls debtor days below 280.
Consolidated debtor days is the single number the market will watch — under 300 re-rates, over 350 confirms the bear case.
8 · For & Against

Lean cautious — cash conversion weighs more than the headline P/E discount

  • For. H1 FY26 inflection is real — ₹67 Cr revenue at 48% OPM, ₹29 Cr PAT exceeds full-year FY25; forward P/E ~12x if sustained (Quant).
  • For. 29x vs. Medanta's 50x at similar ~17% ROCE — discount is wider than the operational gap if Nashik delivers (Quant peer table).
  • For. Founders genuinely aligned — 69% holding rising, zero pledge, ₹4.4 Cr personal loans into the company; MD pay 0.39x median employee (Sherlock).
  • Against. 3-yr cash conversion is 9% — ₹3 Cr CFO on ₹33 Cr PAT; Uganda military owes ₹82 Cr against ₹56 Cr annual revenue (Quant).
  • Against. 21 staff and a 5-person board are commissioning four hospitals in parallel — execution bandwidth is the binding constraint (Warren / Sherlock).
  • Against. 1,000-bed target sits at 252; syringe factory and airline-medical partnerships quietly retired — credibility 5/10 (Historian).
My View — Against weighs more, tipped by cash conversion not valuation. Wait for the FY26 print and Nashik commissioning; flip if debtor days come in under 300 and Navi Mumbai shows 50%+ occupancy.

Watchlist to re-rate: FY26 consolidated debtor days, Nashik commissioning date slippage, Navi Mumbai Q1 FY27 occupancy